LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
89bio Inc.
Headquarters:
San Francisco, CA, United States of America
Website:
https://www.89bio.com/
Year Founded:
2018
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Rohan Palekar, MBA
Number Of Employees:
93
Enterprise Value:
$416,462,274
PE Ratio:
-2.38
Exchange/Ticker 1:
NASDAQ:ETNB
Exchange/Ticker 2:
N/A
Latest Market Cap:
$1,194,148,992
BioCentury
|
Feb 19, 2025
Finance
China competition. Plus: FDA firings and biotech IPOs
Why U.S. biotechs should embrace the challenge from China biotech
Read More
BioCentury
|
Feb 1, 2025
Finance
Metsera, Maze land on NASDAQ as IPO queue grows
BioCentury’s Public Equity Report: MASH data drive follow-ons for Akero, 89bio
Read More
BioCentury
|
Jan 28, 2025
Product Development
Patience pays off for Akero in MASH
After a stumble in 2023, FGF21 agonist demonstrates fibrosis improvement in cirrhosis patients
Read More
BioCentury
|
Nov 15, 2024
Finance
Syncona building Slingshot incubator; Trace launches with $101M
BioCentury’s Financial Report also features venture rounds for Alentis and Metsera; follow-ons for Zai Lab and 89bio
Read More
BioCentury
|
Sep 17, 2024
Management Tracks
Peter Maag resigns as Kyverna CEO
Plus: Ginkgo CEO Jason Kelly steps down from federal biotech advisory group, and updates from Lexicon, Arsenal, Ray and more
Read More
BioCentury
|
Aug 9, 2024
Management Tracks
A quintet of CFO hires at Intra-Cellular, Engrail, Faron, Coherus and Element
Plus: Sarena becomes COO of 89bio
Read More
BioCentury
|
Mar 14, 2024
Regulation
Madrigal’s MASH drug is approved, now it’s time to build the market
FDA approves Rezdiffra as first MASH therapy
Read More
BioCentury
|
Mar 6, 2024
Product Development
Clinical report: Akero’s efruxifermin shows deepening treatment effect at 96 weeks
Plus: Novo positions Ozempic to add CKD to label and updates from Apogee, RegenxBio, Ironwood
Read More
BioCentury
|
Feb 6, 2024
Product Development
Clinical roundup: Data for Lilly’s tirzepatide, GSK’s Blenrep, 4D, Vertex and more
Lilly’s dual GLP-1R/GIP agonist shows early efficacy in MASH; Blenrep combo beats Darzalex combo in MM
Read More
BioCentury
|
Oct 10, 2023
Product Development
Akero’s NASH readout spreads worries to others in class
Despite miss on fibrosis endpoint, biotech touts strong performance on disease resolution, says totality of data support Phase III start
Read More
Items per page:
10
1 - 10 of 39
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa
Help